Pfizer has agreed to divest its 11.7% equity holding in ViiV Healthcare to a consortium led by Shionogi for a total consideration of $1.875 billion. The transaction increases Shionogi’s stake in the HIV specialist to 21.7%, consolidating its position as ViiV’s largest shareholder. Pfizer’s decision to monetize this asset follows a strategic review of non-core businesses and is expected to free up capital for reinvestment in its in-house pipeline and potential acquisitions in immunology and rare disease franchises.

Ahead of its Q4 earnings release, Pfizer forecasts continued strength in Eliquis, projecting year-over-year revenue growth in the mid-teens percentage range driven by expanded indications and patient uptake. At the same time, the company expects COVID-19 vaccine and treatment revenues to decline sharply, reflecting an ongoing shift to endemic management and reduced public demand. Management anticipates that sales of other established non-oncology products, including Prevnar 20 and Xeljanz, will remain broadly flat, underpinning stable cash flow generation as the company rebalances toward routine immunization and specialty care.

In its annual roundup of best ideas for 2026, MoneyShow contributors singled out Pfizer for its strong dividend profile and diversified revenue streams. Analysts noted a current dividend yield in excess of 4%, supported by free cash flow conversion above 25%. They pointed to the company’s robust late-stage pipeline across immunology and rare diseases, along with manufacturing scale that could unlock margin expansion. Pfizer ranks alongside financials and industrials in their defensive growth sleeve, with a consensus upside target of around 15% over the next 12 months.